PEAK6 Investments L.P. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 74.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,342 shares of the medical equipment provider’s stock after purchasing an additional 2,708 shares during the quarter. PEAK6 Investments L.P.’s holdings in Zimmer Biomet were worth $743,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of ZBH. Bronfman E.L. Rothschild L.P. boosted its position in Zimmer Biomet by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares during the period. FNY Managed Accounts LLC acquired a new stake in Zimmer Biomet during the 3rd quarter worth about $117,000. BB&T Investment Services Inc. acquired a new stake in Zimmer Biomet during the 2nd quarter worth about $144,000. Sandy Spring Bank boosted its position in Zimmer Biomet by 5.4% during the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 66 shares during the period. Finally, Penserra Capital Management LLC boosted its position in Zimmer Biomet by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,456 shares of the medical equipment provider’s stock worth $186,000 after acquiring an additional 168 shares during the period. 86.24% of the stock is currently owned by hedge funds and other institutional investors.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded up $0.29 on Thursday, reaching $115.78. The company had a trading volume of 917,100 shares, compared to its average volume of 1,356,597. Zimmer Biomet Holdings, Inc. has a 12-month low of $100.81 and a 12-month high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. The firm has a market cap of $23,383.62, a price-to-earnings ratio of 14.31, a P/E/G ratio of 1.79 and a beta of 1.15.
A number of brokerages have commented on ZBH. Stifel Nicolaus restated a “hold” rating and set a $120.00 price objective on shares of Zimmer Biomet in a research report on Friday, November 3rd. TheStreet lowered Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Friday, November 24th. SunTrust Banks set a $136.00 price objective on Zimmer Biomet and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Piper Jaffray Companies lowered Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 2nd. Finally, Gabelli assumed coverage on Zimmer Biomet in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 price objective for the company. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $133.71.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.